Merck's stock rises on sales of its blockbuster cancer drug Keytruda
Posted
Bruce Gil (via Quartz)
Merck’s stock jumped 3% to about $130 during Thursday morning trading after the New Jersey-based pharmaceutical company reported higher than expected sales of its blockbuster cancer drug Keytruda.Read more...
merck,
blockbuster,
keytruda,
antineoplastic drugs,
health medical pharma,
factset,
pembrolizumab,
schering plough,
pharmaceutical industry,
robert m davis,
kenilworth new jersey,
merck co,
bayer,
business finance,
orphan drugs
